SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Pierre Le Moyne d'Iberville

PatientPierre Le Moyne d'Iberville
Date of birth1982-07-16
IdentifiersMRN HR-ET014-SYN; SSN (made up) 000-14-7260
Document date2026-10-13
AuthorMarguerite Delacroix-Boateng, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Pre-departure review before a naval deployment to French Guiana and the French Antilles. [S]

History of Present Illness

Mr. Le Moyne d'Iberville returns about three months before the squadron sails. He had a sore arm for a day after the vaccines and nothing else. He has had no fever since his malaria treatment seven months ago. He will be aboard ship for the crossing and in the islands, then ashore near Cayenne and Kourou, possibly with river work inland where malaria is transmitted. He will be responsible for the health measures of his crews and wants to set the example. He asked what he should carry. [S]

ElementDetail
Vaccine reactionsSore arm for a day
MalariaNo fever in seven months
ItinerarySea crossing, the Antilles, then French Guiana with possible inland river work
QuestionWhat to carry and how to protect his crews

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or weight loss
GastrointestinalNegativeNo diarrhea
PsychiatricNegativeBusy but well

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total)Oral route2026-03-03 to 2026-03-05completedS
Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days30 mg base once daily for 14 daysOral route2026-03-03 to 2026-03-16completedS
Atovaquone-proguanil 250 mg/100 mg tablet: one tablet daily with food, starting one to two days before entering a malaria area, daily there, and for seven days after leavingonce daily from 1 to 2 days before until 7 days after the malaria areasOral route2026-10-13on-holdS
Azithromycin 500 mg tablet: one tablet daily for up to three days for severe travelers' diarrhea (standby supply)once daily for up to 3 days if neededOral route2026-10-13on-holdS
Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) daily with food for 14 days, starting when he leaves the malaria areas (terminal prophylaxis)30 mg base once daily for 14 days after leaving the malaria areasOral route2026-10-13on-holdS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-13Body height175cmS
2026-10-13Body weight69.2kgS
2026-10-13Body mass index (BMI) [Ratio]22.6kg/m2S
2026-10-13Systolic blood pressure122mm[Hg]S
2026-10-13Diastolic blood pressure76mm[Hg]S
2026-10-13Heart rate64/minS
2026-10-13Respiratory rate14/minS
2026-10-13Body temperature36.6CelS
2026-10-13Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-13Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-17.1 g/dLNormalS
2026-10-13Platelets [#/volume] in Blood by Automated count23610*3/uL150-400 10*3/uLNormalS

Physical Exam

Vital signs recorded on 2026-10-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; temperature 36.6 C, blood pressure 122/76, pulse 64, weight 69.2 kg
AbdomenSpleen not palpable

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requestedresolvedconfirmed R50.9S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation.
Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PDresolvedconfirmed B51.9S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic.
Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccinesactiveconfirmed Z71.84S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705.
Small cutaneous abscess of the right forearm, about 2 cm, from a wooden splinter in the dockyard, without fever, spreading cellulitis or systemic signs; drained, without antibiotics; methicillin-susceptible Staphylococcus aureus on culture; resolvedresolvedconfirmed L02.413S — Synthetic acute problem; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Self-managementRelapse surveillance and the fever action planEvery visitCompleted todayNo fever in seven months; plan extended to travel and after return
LaboratoryPre-departure blood countOnce, before a long deploymentCompleted todayHemoglobin 14.1 g/dL, platelets 236 x10^3/uL
Medication safetyMalaria chemoprophylaxis choice, dosing and interactionsBefore travelCompleted todayAtovaquone-proguanil prescribed; no interacting medicines; take with food
Medication safetyTerminal prophylaxis (presumptive antirelapse therapy) for prolonged P. vivax exposureAfter leaving the malaria areasCompleted todayPrimaquine 30 mg base daily for 14 days prescribed, G6PD normal
ExaminationYellow fever certificate valid on arrivalBefore travelUp to dateVaccinated eleven weeks ago; certificate valid
ExaminationHepatitis B vaccine seriesTwo doses one month apartCompleted todayHepB-CpG dose 2 today
ExaminationHepatitis A vaccine dose 2Six to twelve months after dose 1DueDue after the deployment; dose 1 gives protection for the trip
ExaminationInfluenza vaccineEach seasonCompleted todayGiven today
Self-managementVector avoidance for dengue, chikungunya and typhusBefore and during travelCompleted todayRepellent, permethrin-treated clothing, nets, screens; flea and lice control aboard; no dengue vaccine is recommended for travelers
ExaminationChikungunya vaccineBefore travel, if an outbreak notice appliesDueCDC lists a chikungunya outbreak in French Guiana and recommends vaccination for travelers to outbreak areas; to be decided at a short visit a month before departure against the notice then current
Self-managementFood and water precautions and travelers' diarrhea self-treatmentBefore travelCompleted todayAdvice given; standby azithromycin prescribed

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Influenza vaccine, inactivated, trivalent, preservative-free [S]

Guideline basis: CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Yellow Fever (2026); French Guiana (France): travel health destination page (yellow fever and malaria information updated April 2025) (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Dengue (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Rickettsial Diseases (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Travelers' Diarrhea (2026); The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006)

Follow-up: Short visit a month before departure for the chikungunya vaccine decision. Post-travel visit on return, sooner for any fever. [S]